{"protocolSection": {"identificationModule": {"nctId": "NCT01181895", "orgStudyIdInfo": {"id": "112060"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma", "officialTitle": "A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids"}, "statusModule": {"statusVerifiedDate": "2017-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-09-01"}, "primaryCompletionDateStruct": {"date": "2011-08-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-08-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-07-15", "studyFirstSubmitQcDate": "2010-08-12", "studyFirstPostDateStruct": {"date": "2010-08-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-06-06", "resultsFirstSubmitQcDate": "2013-08-22", "resultsFirstPostDateStruct": {"date": "2013-08-26", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-07-26", "dispFirstSubmitQcDate": "2012-07-26", "dispFirstPostDateStruct": {"date": "2012-08-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-10-09", "lastUpdatePostDateStruct": {"date": "2017-11-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 348, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Vilanterol", "type": "EXPERIMENTAL", "description": "Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks", "interventionNames": ["Drug: Vilanterol", "Drug: Placebo Inhalation Powder Diskus"]}, {"label": "Salmeterol", "type": "ACTIVE_COMPARATOR", "description": "Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks", "interventionNames": ["Drug: Salmeterol Inhalation Powder", "Drug: Placebo Inhalation Powder NDPI"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks", "interventionNames": ["Drug: Placebo Inhalation Powder NDPI", "Drug: Placebo Inhalation Powder Diskus"]}], "interventions": [{"type": "DRUG", "name": "Vilanterol", "description": "Vilanterol inhalation powder inhaled orally once daily for 12 weeks", "armGroupLabels": ["Vilanterol"]}, {"type": "DRUG", "name": "Salmeterol Inhalation Powder", "description": "Salmeterol inhalation powder inhaled orally twice daily for 12 weeks", "armGroupLabels": ["Salmeterol"]}, {"type": "DRUG", "name": "Placebo Inhalation Powder NDPI", "description": "Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler", "armGroupLabels": ["Placebo", "Salmeterol"]}, {"type": "DRUG", "name": "Placebo Inhalation Powder Diskus", "description": "Placebo inhalation powder inhaled orally twice daily for 12 weeks", "armGroupLabels": ["Placebo", "Vilanterol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12", "description": "FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Weeks 1-12"}, {"measure": "Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Weeks 1-12"}, {"measure": "Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points", "description": "FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Weeks 1-12"}, {"measure": "Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "timeFrame": "Baseline and Weeks 1-12"}, {"measure": "Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)", "description": "The number of participants with a \\>=12% and \\>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a \\>=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a \\>=12% and \\>=200 mL increase from Baseline in FEV1 over this time period were considered censored.", "timeFrame": "Day 1 and Week 12"}, {"measure": "Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12", "description": "At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.", "timeFrame": "Week 4 and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Outpatient at least 12 years of age\n* Both genders; females of childbearing potential must be willing to use birth control method\n* Clinical diagnosis of asthma for \u226512 weeks\n* Best pre-bronchodilator FEV1 of 40%-90% predicted\n* Reversibility of FEV1 of at least 12% and 200mls\n* Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks prior to 1st visit\n* Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits\n\nExclusion Criteria:\n\n* History of life-threatening asthma\n* Respiratory infection within last 4 weeks leading to change in asthma management\n* Asthma exacerbation within last 3 months\n* Concurrent respiratory disease or other disease that would confound study participation or affect subject safety\n* Allergies to study drugs, study drugs' excipients, or medications related to study drugs\n* Taking another investigational medication or medication prohibited for use during the study.\n* Previous participation in a vilanterol (GW642444) study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "GSK Investigational Site", "city": "Orlando", "state": "Florida", "zip": "32822", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "GSK Investigational Site", "city": "Tallahassee", "state": "Florida", "zip": "32308", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "GSK Investigational Site", "city": "Lawrenceville", "state": "Georgia", "zip": "30046", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "GSK Investigational Site", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "GSK Investigational Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Chester", "state": "South Carolina", "zip": "29706", "country": "United States", "geoPoint": {"lat": 34.70486, "lon": -81.21426}}, {"facility": "GSK Investigational Site", "city": "Clinton", "state": "South Carolina", "zip": "29325", "country": "United States", "geoPoint": {"lat": 34.47263, "lon": -81.88066}}, {"facility": "GSK Investigational Site", "city": "Orangeburg", "state": "South Carolina", "zip": "29118", "country": "United States", "geoPoint": {"lat": 33.49182, "lon": -80.85565}}, {"facility": "GSK Investigational Site", "city": "Gauting", "state": "Bayern", "zip": "82131", "country": "Germany", "geoPoint": {"lat": 48.06919, "lon": 11.37703}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Mainz", "state": "Rheinland-Pfalz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "GSK Investigational Site", "city": "Grosshansdorf", "state": "Schleswig-Holstein", "zip": "22927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "GSK Investigational Site", "city": "Callao", "state": "Lima", "zip": "Callao 2", "country": "Peru", "geoPoint": {"lat": -12.05659, "lon": -77.11814}}, {"facility": "GSK Investigational Site", "city": "Lima 27", "state": "Lima", "zip": "Lima 27", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "GSK Investigational Site", "city": "San Isidro", "state": "Lima", "zip": "Lima 27", "country": "Peru", "geoPoint": {"lat": -12.11667, "lon": -77.05}}, {"facility": "GSK Investigational Site", "city": "San Miguel", "state": "Lima", "zip": "Lima 32", "country": "Peru", "geoPoint": {"lat": -13.0125, "lon": -73.98083}}, {"facility": "GSK Investigational Site", "city": "Lima", "zip": "Lima 27", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "GSK Investigational Site", "city": "Chrzanow", "zip": "32-500", "country": "Poland", "geoPoint": {"lat": 50.13546, "lon": 19.40203}}, {"facility": "GSK Investigational Site", "city": "Krakow", "zip": "30-901", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "GSK Investigational Site", "city": "Krakow", "zip": "31-024", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "GSK Investigational Site", "city": "Krakow", "zip": "31-455", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "GSK Investigational Site", "city": "Lublin", "zip": "20-552", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49027", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49074", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Donetsk", "zip": "83099", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "GSK Investigational Site", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "GSK Investigational Site", "city": "Kharkiv", "zip": "61037", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "GSK Investigational Site", "city": "Kharkiv", "zip": "61124", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Simferopol", "zip": "95043", "country": "Ukraine", "geoPoint": {"lat": 44.95719, "lon": 34.11079}}, {"facility": "GSK Investigational Site", "city": "Yalta", "zip": "98603", "country": "Ukraine", "geoPoint": {"lat": 44.50218, "lon": 34.16624}}]}, "referencesModule": {"references": [{"pmid": "24928338", "type": "DERIVED", "citation": "Lotvall J, Bateman ED, Busse WW, O'Byrne PM, Woodcock A, Toler WT, Jacques L, Goldfrad C, Bleecker ER. Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. J Negat Results Biomed. 2014 Jun 13;13(1):9. doi: 10.1186/1477-5751-13-9."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "112060", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112060", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112060", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112060", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112060", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112060", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "112060", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants (par.) meeting eligibility criteria at the Screening visit completed a 28-day Run-in Period for Baseline, safety evaluations, and measures of asthma status. Par. were then randomized to an 8-week Treatment Period. A total of 583 par. were screened, and 347 were randomized, of which 298 received at least one dose of study treatment.", "recruitmentDetails": "347 participants (par.) were randomized to treatment; all 347 were included in the Intent-to-Treat (ITT) Population. One par. was not randomized but received treatment in error. This par. was not included in the ITT Population and is thus not captured in the Participant Flow module. This par. is categorized as being enrolled in the study (n=348).", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "FG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "FG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "116"}, {"groupId": "FG001", "numSubjects": "115"}, {"groupId": "FG002", "numSubjects": "116"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "99"}, {"groupId": "FG001", "numSubjects": "101"}, {"groupId": "FG002", "numSubjects": "98"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "18"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Investigator Discretion", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "BG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "BG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}, {"groupId": "BG001", "value": "115"}, {"groupId": "BG002", "value": "116"}, {"groupId": "BG003", "value": "347"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.7", "spread": "16.64"}, {"groupId": "BG001", "value": "41.0", "spread": "17.81"}, {"groupId": "BG002", "value": "41.1", "spread": "16.84"}, {"groupId": "BG003", "value": "41.3", "spread": "17.06"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "77"}, {"groupId": "BG003", "value": "204"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "39"}, {"groupId": "BG003", "value": "143"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "22"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "41"}, {"groupId": "BG003", "value": "122"}]}]}, {"title": "Japanese/East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "68"}, {"groupId": "BG003", "value": "202"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12", "description": "FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.", "populationDescription": "Intent-to-Treat (ITT) Population: all participants randomized to treatment who received at least one dose of study medication. Only those participants available at the indicated time point were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.289", "spread": "0.0429"}, {"groupId": "OG001", "value": "0.359", "spread": "0.0416"}, {"groupId": "OG002", "value": "0.283", "spread": "0.0419"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.244", "pValueComment": "P-value for the adjusted treatment difference for Vilanterol 25 \u00b5g OD versus Placebo.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.070", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.048", "ciUpperLimit": "0.188", "estimateComment": "The estimated value represents the adjusted treatment difference in the weighted mean 0-24 hour FEV1 (Liters) at Week 12 for Vilanterol 25 \u00b5g OD versus Placebo."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.926", "pValueComment": "P-value for the adjusted treatment difference for Salmetarol 50 \u00b5g BID versus Placebo.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.006", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.124", "ciUpperLimit": "0.113", "estimateComment": "The estimated value represents the adjusted treatment difference in the weighted mean 0-24 hour FEV1 (Liters) at Week 12 for Salmeterol 50 \u00b5g BID versus Placebo."}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "ITT Population. Only those participants available at the indicated time points were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of rescue-free 24-hr periods", "timeFrame": "Baseline and Weeks 1-12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.6", "spread": "2.71"}, {"groupId": "OG001", "value": "21.7", "spread": "2.68"}, {"groupId": "OG002", "value": "22.9", "spread": "2.72"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "ITT Population. Only those participants available at the indicated time points were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of symptom-free 24-hr periods", "timeFrame": "Baseline and Weeks 1-12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.7", "spread": "2.58"}, {"groupId": "OG001", "value": "19.4", "spread": "2.55"}, {"groupId": "OG002", "value": "19.5", "spread": "2.59"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points", "description": "FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point.", "populationDescription": "ITT Population. Only those participants available at the indicated time points were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "116"}]}], "classes": [{"title": "Predose, n=97,104,101", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.302", "spread": "0.0446"}, {"groupId": "OG001", "value": "0.272", "spread": "0.0430"}, {"groupId": "OG002", "value": "0.233", "spread": "0.0437"}]}]}, {"title": "5 min, n=95,100,98", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.313", "spread": "0.0450"}, {"groupId": "OG001", "value": "0.301", "spread": "0.0438"}, {"groupId": "OG002", "value": "0.214", "spread": "0.0443"}]}]}, {"title": "15 min, n=96, 101, 99", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.308", "spread": "0.0450"}, {"groupId": "OG001", "value": "0.324", "spread": "0.0439"}, {"groupId": "OG002", "value": "0.257", "spread": "0.0444"}]}]}, {"title": "30 min, n=,96,101,100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.322", "spread": "0.0443"}, {"groupId": "OG001", "value": "0.344", "spread": "0.0432"}, {"groupId": "OG002", "value": "0.272", "spread": "0.0435"}]}]}, {"title": "60 min, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.336", "spread": "0.0445"}, {"groupId": "OG001", "value": "0.352", "spread": "0.0433"}, {"groupId": "OG002", "value": "0.296", "spread": "0.0437"}]}]}, {"title": "2 hours, n=96, 100, 99", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.313", "spread": "0.0455"}, {"groupId": "OG001", "value": "0.369", "spread": "0.0446"}, {"groupId": "OG002", "value": "0.335", "spread": "0.0449"}]}]}, {"title": "3 hours, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.304", "spread": "0.0455"}, {"groupId": "OG001", "value": "0.374", "spread": "0.0444"}, {"groupId": "OG002", "value": "0.316", "spread": "0.0447"}]}]}, {"title": "4 hours, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.311", "spread": "0.0450"}, {"groupId": "OG001", "value": "0.359", "spread": "0.0438"}, {"groupId": "OG002", "value": "0.293", "spread": "0.0441"}]}]}, {"title": "5 hours, n=96, 100, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.292", "spread": "0.0455"}, {"groupId": "OG001", "value": "0.368", "spread": "0.0445"}, {"groupId": "OG002", "value": "0.279", "spread": "0.0447"}]}]}, {"title": "11 hours, n=94, 99, 96", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.195", "spread": "0.0508"}, {"groupId": "OG001", "value": "0.312", "spread": "0.0494"}, {"groupId": "OG002", "value": "0.179", "spread": "0.0505"}]}]}, {"title": "12 hours, n=93,98,95", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.250", "spread": "0.0477"}, {"groupId": "OG001", "value": "0.341", "spread": "0.0465"}, {"groupId": "OG002", "value": "0.217", "spread": "0.0473"}]}]}, {"title": "12.5 hours, n=96, 97, 98", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.270", "spread": "0.0446"}, {"groupId": "OG001", "value": "0.337", "spread": "0.0444"}, {"groupId": "OG002", "value": "0.282", "spread": "0.0443"}]}]}, {"title": "13 hours, 96, 98, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.312", "spread": "0.0448"}, {"groupId": "OG001", "value": "0.341", "spread": "0.0442"}, {"groupId": "OG002", "value": "0.304", "spread": "0.0440"}]}]}, {"title": "14 hours, n=95, 99, 99", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.341", "spread": "0.0445"}, {"groupId": "OG001", "value": "0.401", "spread": "0.0436"}, {"groupId": "OG002", "value": "0.359", "spread": "0.0437"}]}]}, {"title": "16 hours, n=95, 98, 97", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.364", "spread": "0.0464"}, {"groupId": "OG001", "value": "0.371", "spread": "0.0457"}, {"groupId": "OG002", "value": "0.357", "spread": "0.0461"}]}]}, {"title": "20 hours, n= 94, 101, 99", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.318", "spread": "0.0485"}, {"groupId": "OG001", "value": "0.371", "spread": "0.0467"}, {"groupId": "OG002", "value": "0.296", "spread": "0.0473"}]}]}, {"title": "23 hours, 94, 101, 99", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.310", "spread": "0.0456"}, {"groupId": "OG001", "value": "0.345", "spread": "0.0440"}, {"groupId": "OG002", "value": "0.271", "spread": "0.0446"}]}]}, {"title": "24 hours, n= 95, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.301", "spread": "0.0445"}, {"groupId": "OG001", "value": "0.330", "spread": "0.0432"}, {"groupId": "OG002", "value": "0.275", "spread": "0.0435"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "ITT Population. Only those participants available at the indicated time points were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters per minute (L/min)", "timeFrame": "Baseline and Weeks 1-12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.0", "spread": "3.15"}, {"groupId": "OG001", "value": "24.9", "spread": "3.14"}, {"groupId": "OG002", "value": "18.8", "spread": "3.17"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.", "populationDescription": "ITT Population. Only those participants available at the indicated time points were assessed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters per minute (L/min)", "timeFrame": "Baseline and Weeks 1-12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.2", "spread": "3.25"}, {"groupId": "OG001", "value": "28.0", "spread": "3.24"}, {"groupId": "OG002", "value": "23.6", "spread": "3.27"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)", "description": "The number of participants with a \\>=12% and \\>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a \\>=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a \\>=12% and \\>=200 mL increase from Baseline in FEV1 over this time period were considered censored.", "populationDescription": "ITT Population. Only those participants available at the indicated time points were assessed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Day 1 and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "113"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "116"}]}], "classes": [{"title": "Day 1, 5 min, n=113, 115, 116", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "18"}]}]}, {"title": "Day 1, 15 min, n=113, 115, 116", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Day 1, 30 min, n=113, 115, 1116", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Day 1, 1 hr, n=113, 115, 116", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Day 1, 2 hr, n=113, 115, 116", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Day 1, Censored, n=113, 115, 116", "categories": [{"measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "57"}]}]}, {"title": "Week 12, 5 min, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "30"}]}]}, {"title": "Week 12, 15 min, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Week 12, 30 min, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Week 12, 1 hr, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Week 12, 2 hr, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Week 12, Censored, n=96, 101, 100", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "46"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12", "description": "At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.", "populationDescription": "ITT Population. Only those participants available at the indicated time points were assessed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 4 and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study."}, {"id": "OG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "110"}]}], "classes": [{"title": "Week 4, AS: Much better, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "34"}]}]}, {"title": "Week 4, AS: Somewhat better, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "34"}]}]}, {"title": "Week 4, AS: A little better, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Week 4, AS: The same, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "16"}]}]}, {"title": "Week 4, AS: A little worse, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Week 4, AS: Somewhat worse, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Week 4, AS: Much worse, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Week 4, RMU: Much less often, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "28"}]}]}, {"title": "Week 4, RMU: Somewhat less often, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "36"}]}]}, {"title": "Week 4, RMU: A little less often, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "20"}]}]}, {"title": "Week 4, RMU: The same, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "17"}]}]}, {"title": "Week 4, RMU: A little more often, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Week 4, RMU: Somewhat more often, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Week 4, RMU: Much more often, n=110, 109, 110", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Week 12, AS: Much better, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "35"}]}]}, {"title": "Week 12, AS: Somewhat better, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "34"}]}]}, {"title": "Week 12, AS: A little better, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "16"}]}]}, {"title": "Week 12, AS: The same, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Week 12, AS: A little worse, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Week 12, AS: Somewhat worse, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Week 12, AS: Much worse, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Week 12, RMU: Much less often, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "32"}]}]}, {"title": "Week 12, RMU: Somewhat less often, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "29"}]}]}, {"title": "Week 12, RMU: A little less often, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Week 12, RMU: The same, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Week 12, RMU: A little more often, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Week 12, RMU: Somewhat more often, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Week 12, RMU: Much more often, n=100, 105, 101", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol inhalation aerosol to be used as needed throughout the study.", "seriousNumAffected": 1, "seriousNumAtRisk": 116, "otherNumAffected": 26, "otherNumAtRisk": 116}, {"id": "EG001", "title": "Vilanteral 25 \u00b5g OD", "description": "Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.", "seriousNumAffected": 1, "seriousNumAtRisk": 115, "otherNumAffected": 26, "otherNumAtRisk": 115}, {"id": "EG002", "title": "Salmeterol 50 \u00b5g BID", "description": "Participants received Salmeterol 50 \u00b5g BID from the DISKUS/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol/salbutamol aerosol to be used as needed throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 116, "otherNumAffected": 21, "otherNumAtRisk": 116}], "seriousEvents": [{"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 116}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 116}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 116}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 116}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 116}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 116}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}